Table 1 Characteristics of included studies
Study groups | Number of patients | Intervention | Wks of follow-up | Study design | Mean baseline scores (SD) | Mean change scores (SD) | Order of questionnaires randomized | Use of validated questionnaires | ||
|---|---|---|---|---|---|---|---|---|---|---|
CRQ | SGRQ | CRQ | SGRQ | |||||||
Barr [18] | 102 | Respiratory rehabilitation (RP) | 4 | Prospective follow-up study | 3.89 (0.89) | 55.8 (17.9) | 0.71 (0.75) | -3.00 (12.20) | No | Yes |
Bestall [14] | 23 | RP | 52 | RCT | 4.00 (0.90) | 51.0 (13.7) | 0.35 (0.85) | -3.00 (12.20) | No | Yes |
Bestall [14] | 21 | Patient education | 52 | RCT | 4.28 (0.98) | 51.9 (13.9) | -0.05 (0.58) | -1.00 (9.35) | No | Yes |
Bourbeau [22] | 65 | RP | 2 | Prospective follow-up study | n.a. | n.a. | 0.74 (0.74) | -7.20 (12.30) | Yes | Yes |
Bourbeau [22] | 27 | Usual care | 2 | Prospective follow-up study | n.a. | n.a. | 0.35 (0.31) | -2.40 (5.57) | Yes | Yes |
Connor [16] | 170 | RP | 52 | Prospective follow-up study | n.a. | 51.6 (15.8) | n.a. | n.a. | No | Yes |
Desikan [23] | 40 | Usual care | 12 | Prospective follow-up study | 3.75 (0.95) | 50.2 (18.5) | 0.33 (0.86) | -2.51 (9.71) | Yes | Yes |
de Torres [19] | 37 | RP | 8 | Prospective follow-up study | 4.13 (0.95) | 52.0 (13.0) | 0.56 (1.20) | -4.00 (13.40) | No | Yes |
Griffiths [20] | 37 | RP | 52 | RCT | 3.59 (0.95) | 64.9 (12.7) | 0.25 (0.80) | -3.40 10.86) | No | Yes |
Griffiths [20] | 33 | Usual care | 52 | RCT | 3.53 (0.95) | 68.3 (13.3) | -0.08 (0.80) | 0.70 (10.86) | No | Yes |
Hajiro [24] | 165 | Usual care | 12 | Prospective follow-up study | 5.31 (0.97) | 40.3 (20.1) | 0.65 (0.83) | -6.00 (18.50) | No | Yes |
Harper [25] | 156 | Usual care | 26 | Prospective follow-up study | 3.69 (0.95) | 65.4 (15.9) | 0.07 (1.00) | 0.81 (9.95) | No | Yes |
Man [17] | 21 | RP | 18 | RCT | 2.64 (0.95) | 65.4 (13.5) | 1.87 (0.53) | -16.10 (5.95) | No | Yes |
Man [17] | 21 | Usual care | 16 | RCT | 3.11 (0.95) | 69.6 (13.6) | 0.49 (0.26) | -3.40 (8.50) | No | Yes |
Rutten [9] | 47 | Salmeterol + Ipratropium | 12 | RCT | 4.44 (0.81) | 48.3 (13.9) | 0.20 (0.60) | -2.40 (11.00) | No | Yes |
Rutten [9] | 47 | Salmeterol + Placebo | 12 | RCT | 4.58 (1.03) | 50.5 (16.6) | -0.19 (0.80) | -0.01 (7.10) | No | Yes |
Rutten [9] | 50 | Placebo | 12 | RCT | 4.22 (1.05) | 50.2 (15.8) | 0.03 (0.70) | 0.50 (9.20) | No | Yes |
Singh [12] | 97 | RP | 7 | Prospective follow-up study | 3.66 (0.92) | 58.8 (15.2) | 0.72 (1.00) | -4.02 (12.98) | No | Yes |
Schunemann [8] | 84 | RP | 12 | Prospective follow-up study | 4.01 (0.95) | 52.8 (13.9) | 1.14 (0.90) | -8.10 (20.40) | Yes | Yes |
Schunemann [10] | 183 | RP | 12 | Prospective follow-up study | 4.57 (0.95) | 50.6 (13.9) | 0.55 (0.89) | -5.43 (11.18) | Yes | Yes |
Wedzicha [15] | 26 | RP on | 8 | RCT | 3.76 (0.90) | 56.7 (14.0) | 0.20 (0.39) | 3.00 (10.40) | No | Yes |
Wedzicha [15] | 28 | Patient education | 8 | RCT | 3.82 (1.20) | 59.1 (13.0) | 0.20 (0.32) | 2.00 (8.10) | No | Yes |